Group 1 - The independent director Bai Yan of Guoxin Health passed away due to illness on August 31, 2025 [1][4] - Bai Yan served as the chairman of the Compensation and Assessment Committee, a member of the Audit Committee, and a member of the Nomination Committee during his tenure [1][4] - Guoxin Health expressed deep condolences and gratitude for Bai Yan's contributions, stating that his passing is a loss for the board [4][5] Group 2 - Following Bai Yan's death, the number of board members at Guoxin Health decreased from 9 to 8, which is still above the legal minimum but below the number stipulated in the company's articles of association [4] - The company plans to complete the independent director replacement process in accordance with relevant regulations and will fulfill its information disclosure obligations [4]

Core Viewpoint - The article reports the passing of Bai Yan, an independent director of Guo Xin Health, due to illness, highlighting his contributions and the company's plans for board member replacement [1][3][4]. Summary by Sections Announcement of Passing - Guo Xin Health announced the death of independent director Bai Yan on August 31, 2025, due to illness [1][3]. - Bai Yan served as the chairman of the Compensation and Assessment Committee and was a member of the Audit and Nomination Committees [1]. Contributions and Legacy - Bai Yan was recognized for his diligence and commitment to his duties, providing professional opinions and safeguarding the interests of minority shareholders during his tenure [3]. - The company expressed deep condolences and gratitude for Bai Yan's efforts and contributions [3]. Board Composition Changes - Following Bai Yan's passing, the board's membership decreased from 9 to 8, remaining above the legal minimum but below the number stipulated in the company's articles of association [3]. - Guo Xin Health plans to conduct a replacement for the independent director in accordance with relevant regulations [3]. Background of Bai Yan - Bai Yan, aged 60, held a Ph.D. from Peking University and had a distinguished academic and professional career, including roles as a professor and external director in various organizations [4]. - He was noted for his integrity, optimism, and contributions to academia and society [4].

关于公司独立董事去世的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）董事会近日获悉， 公司独立董事白彦先生于 2025 年 8 月 31 日不幸因病去世。公司及公司董事会对 白彦先生的去世致以沉痛哀悼，并向其家人表示深切慰问。 白彦先生在担任公司董事会独立董事、薪酬与考核委员会主任委员、审计委 员会委员、提名委员会委员期间，恪尽职守，勤勉尽责，忠实地履行了作为独立 董事应尽的职责和义务，为公司相关决策事项提供了专业意见和建议，积极维护 中小股东利益。白彦先生的去世是公司董事会的损失，我们深切缅怀白彦先生， 公司及公司董事会对白彦先生在任职期间所付出的辛勤努力和贡献，致以最崇高 的敬意和最衷心的感谢。 证券简称：国新健康 证券代码：000503 编号：2025-52 国新健康保障服务集团股份有限公司 白彦先生去世后，公司现任董事会成员由 9 名变为 8 名，未低于法定最低人 数，但低于《公司章程》规定的董事会成员人数和独立董事人数，公司独立董事 人数低于董事会成员的三分之一。公司将根据《公司法》《公司章 ...

人民财讯9月4日电，国新健康（000503）9月4日晚间公告，公司董事会近日获悉，公司独立董事白彦于 2025年8月31日不幸因病去世。公司及公司董事会对白彦的去世致以沉痛哀悼，并向其家人表示深切慰 问。 ...

Core Insights - The company reported a revenue of 95.53 million, representing a year-on-year decline of 30.47% [1] - The net loss attributable to shareholders was 99.09 million, an increase from a loss of 72.98 million in the same period last year [1] Revenue Breakdown - **By Industry**: - Service industry revenue was 95.53 million with a gross margin of -15.20%, down 30% year-on-year [2] - **By Product**: - Digital Medical Insurance: Revenue of 49.70 million, cost of 61.76 million, gross margin of -24.26%, down 6% year-on-year [2] - Digital Healthcare: Revenue of 16.91 million, cost of 18.99 million, gross margin of -12.28%, down 64% year-on-year [2] - Digital Pharmaceuticals: Revenue of 25.00 million, cost of 23.51 million, gross margin of 5.96%, up 80% year-on-year [2] - Health Services: Revenue of 3.83 million, cost of 5.77 million, gross margin of -50.58%, down 82% year-on-year [2] Strategic Focus - The company is driven by a strategy of "Three Medical Collaborations, Innovation-Driven, Digital Ecosystem," focusing on the informatization, digitalization, and intelligence of the healthcare industry [2] - The main business segments include Digital Medical Insurance, Digital Healthcare, Digital Pharmaceuticals, and Health Services, with an emphasis on the value of health big data [2]

Core Viewpoint - Guoxin Health (000503.SZ) reported a significant decline in revenue and incurred substantial losses in the first half of 2025 [1] Financial Performance - The company achieved operating revenue of 95.53 million yuan, representing a year-on-year decrease of 30.47% [1] - The net loss attributable to shareholders of the listed company was 99.09 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 98.81 million yuan [1] - The basic loss per share was 0.1012 yuan [1]

Core Viewpoint - Guoxin Health (000503.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 95.53 million yuan, a year-on-year decrease of 30.47% [1] - The net profit attributable to shareholders was -99.09 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -98.81 million yuan [1] - Basic earnings per share were -0.1012 yuan [1]

证券简称：国新健康 证券代码：000503 编号：2025-50 国新健康保障服务集团股份有限公司 第十二届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届监事 会第三次会议于2025年8月15日发出会议通知，会议由监事会主席程志鹏先生召 集并主持，于2025年8月26日以现场结合通讯方式召开。本次会议应出席监事3 人，实际出席监事3人。会议的召开符合有关法律、行政法规、部门规章和《公 司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、公司 2025 年半年度报告及摘要 经审核，监事会认为董事会编制和审议公司2025年半年度报告的程序符合 法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容能够真 实、准确、完整地反映上市公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 表决情况：3票赞成、0票反对、0票弃权。 具体内容详见同日在《中国证券报》《上海证券报》《证券时报》及巨潮 资讯网（网址：www.cninfo.com.cn）披露的 ...

证券简称：国新健康 证券代码：000503 编号：2025-49 国新健康保障服务集团股份有限公司 表决结果：9票赞成，0票反对，0票弃权。 具体内容详见同日在巨潮资讯网（网址：www.cninfo.com.cn）披露的公司 《2025年半年度募集资金存放与使用情况专项报告》。 三、公司2025年半年度关于国新集团财务有限责任公司风险持续评估报告 第十二届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届董事 会第三次会议于2025年8月15日发出会议通知，会议由董事长李永华先生召集并 主持，于2025年8月26日以现场结合通讯方式召开。本次会议应出席董事9人， 实际出席董事9人，公司监事和高级管理人员列席会议。会议的召开符合有关法 律、行政法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、公司2025年半年度报告及摘要 表决情况：9票赞成，0票反对，0票弃权。 具体内容详见同日在《中国证券报》《上海证券报》《证券时报》及巨潮 资讯网（网 ...

国新健康公告，2025年上半年营业收入9553.01万元，同比下降30.47%。净亏损9909.07万元，上年同期 净亏损7298.15万元。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...